



49913

**BRAWN BIOTECH LTD.****13th August 2025**

**The General Manager
The Department of Corporate Services,
BSE Limited, 25th Floor,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai -400001**

**BSE Scrip Code: 530207
Scrip ID: BRAWN**

Sub: Outcome of the Board Meeting of the Company held on 13th August 2025, and submissions of Un-Audited Financial Results for the Quarter 30.06.2025.

Ref: Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (SEBI Listing regulations).

Dear Sir/Ma'am,

With reference to the captioned subject and pursuant to the provisions of Regulation 30 and Regulation 33 of SEBI Listing Regulations, this is to inform you that the Board of Directors of the Company in its meeting held today, 13th August 2025 has considered and approved the Un-Audited Financial Results along with Limited Review Report by the Company's Statutory Auditor for the quarter ended 30th June, 2025 a Copy of which is enclosed herewith.

We wish to further inform you that the meeting of the board of directors commenced at 01:00 P.M. and concluded at 02:00 P.M.

Kindly take the same on your record and acknowledge receipt of the same.

Thanking You.

**For and on behalf of
Brawn Biotech Limited**



**Priyanka Sharma
Company Secretary and Compliance Officer
Membership No.: A50385
Encl: As above**

**BRAWN BIOTECH LTD.****CIN NO.: L74899DL1985PLC022468**

Works : Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA
Email: distribution@brawnlabs.in | Website : www.brawngroup.in
Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331
Email: solution@brawnbiotech.com

...for better life



BRAWN BIOTECH LTD.

BRAWN BIOTECH LIMITED				
CIN:L74899DL1985PLC022468				
REGD. OFFICE: C-64 Lajpat Nagar-1 Delhi 110024				
STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2025				
Rs. in Lacs				
Sr. No.	Particulars	Quarter Ended		Year Ended
		30-Jun-25	31-Mar-25	31-Mar-25
		Un-audited	Audited	Audited
1	Revenue from operations			
	Revenue from operations	579.77	225.93	1,346.50
	Other Income	9.09	9.12	9.33
	Total Revenue	588.86	235.04	1,355.83
2	Expenses			
a	Cost of material consumed	-	-	-
b	Purchase of stock-in-trade	391.21	318.00	1,638.05
c	Change in inventories of finished goods, work in progress and stock in trade	104.92	(122.84)	(445.04)
d	Employee Benefit expenses	20.52	22.49	112.63
e	Depreciation and amortisation expenses	3.07	3.13	11.46
f	Finance Cost	0.03	0.21	0.37
g	Other expenses	45.51	63.50	218.17
	Total Expenses	565.26	284.49	1,535.64
3	Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)	23.60	(49.44)	(179.81)
4	Other Income	-	-	-
5	Profit from ordinary activities before exceptional items (3-4)	23.60	(49.44)	(179.81)
6	Exceptional Items	-	-	-
7	Profit from ordinary activities before tax (5-6)	23.60	(49.44)	(179.81)
8	Tax Expenses	-	-	-
9	Profit (Loss) for the period from continuing operations (7-8)	23.60	(49.44)	(179.81)
10	Profit/(loss) from discontinuing operations	-	-	-
11	Tax expense of discontinuing operations	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-
13	Profit (Loss) for the period (9+12)	23.60	(49.44)	(179.81)
14	Other Comprehensive Income	3.20	(0.08)	3.73
	Total Comprehensive Income	26.80	(49.52)	(176.08)
15	Details of equity share capital	300.03	300.03	300.03
	Paid-up equity share capital			
	Face value of equity share capital			
16	Reserve excluding Revaluation Reserve			
17	Earnings per share			
i	Basic earnings per share	0.89	(1.65)	(5.87)
ii	Diluted earnings per share	0.89	(1.65)	(5.87)

NOTES:-

- Results for the quarter ended on 30th June, 2025 were reviewed by the Audit committee and then approve by the Board of Directors at their meeting held on 13th August, 2025.
- The Statutory Auditors carried out the limited review for quarter ended 30th June, 2025. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Un-audited Financial Results for the quarter ended on 30.06-2025 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited

Brij Raj Gupta
Director
DIN NO. 00974969
Date : 13-08-2025
Place: Delhi



BRAWN BIOTECH LTD.

CIN NO.: L74899DL1985PLC022468

Works : Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA
Email: distribution@brawnlabs.in | Website : www.brawngroup.in
Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331
Email: solution@brawnbiotech.com

...for better life



RAJIV UDAI & ASSOCIATES
CHARTERED ACCOUNTANTS

To,
The Board of Directors of
Brawn Biotech Limited

We have reviewed the accompanying statement of unaudited financial results of **Brawn Biotech Limited** for the quarter ended 30th June 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


This Statement, which is the responsibility and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 018764N


Rajeev Jain
Partner

Membership No. 099767
UDIN: 25099767BMIVIK5387



Place: Delhi
Date: 13-08-2025